Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:ASBP NASDAQ:ENTO NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.09+1.8%$1.48$0.84▼$8.22$4.14M0.11121,970 shs45,335 shsASBPAspire Biopharma$0.19-3.5%$0.89$0.16▼$35.01$969K0.217.87 million shs3.18 million shsENTOEntero Therapeutics$2.52+0.4%$2.31$0.32▼$5.84$4.00M1.192.80 million shs44,088 shsREVBRevelation Biosciences$1.03-4.2%$1.22$0.99▼$40.08$3.81M-0.14492,061 shs84,587 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-4.46%-2.73%+7.01%-48.56%-82.52%ASBPAspire Biopharma-5.75%-4.17%-80.39%-87.10%+19,999,900.00%ENTOEntero Therapeutics0.00%+12.00%+5.44%-19.49%+137.69%REVBRevelation Biosciences-4.46%-7.76%-14.40%-32.70%-96.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.09+1.8%$1.48$0.84▼$8.22$4.14M0.11121,970 shs45,335 shsASBPAspire Biopharma$0.19-3.5%$0.89$0.16▼$35.01$969K0.217.87 million shs3.18 million shsENTOEntero Therapeutics$2.52+0.4%$2.31$0.32▼$5.84$4.00M1.192.80 million shs44,088 shsREVBRevelation Biosciences$1.03-4.2%$1.22$0.99▼$40.08$3.81M-0.14492,061 shs84,587 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-4.46%-2.73%+7.01%-48.56%-82.52%ASBPAspire Biopharma-5.75%-4.17%-80.39%-87.10%+19,999,900.00%ENTOEntero Therapeutics0.00%+12.00%+5.44%-19.49%+137.69%REVBRevelation Biosciences-4.46%-7.76%-14.40%-32.70%-96.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$28.002,471.17% UpsideASBPAspire Biopharma 1.00SellN/AN/AENTOEntero Therapeutics 1.00SellN/AN/AREVBRevelation Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ASBP, ALZN, REVB, and ENTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/20/2026ASBPAspire Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AASBPAspire Biopharma$10K96.89N/AN/A($1.80) per share-0.11ENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$1.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%N/AASBPAspire Biopharma-$24.48M-$20.00N/AN/AN/AN/AN/A-1,468.13%N/AENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%5/13/2026 (Estimated)REVBRevelation Biosciences-$8.91M-$62.09N/AN/AN/AN/A-134.18%-105.47%5/7/2026 (Estimated)Latest ASBP, ALZN, REVB, and ENTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026N/AREVBRevelation Biosciences-$1.15N/AN/AN/AN/AN/A3/30/2026Q4 2025ASBPAspire BiopharmaN/A-$0.0550N/A-$15.95N/A$0.00 million3/11/2026Q3 2026ALZNAlzamend Neuro-$0.53-$0.5780-$0.0480-$0.58N/AN/A2/26/2026Q4 2025REVBRevelation Biosciences-$1.41-$1.65-$0.24-$1.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AASBPAspire BiopharmaN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A1.991.99ASBPAspire BiopharmaN/A0.170.14ENTOEntero TherapeuticsN/A2.622.62REVBRevelation BiosciencesN/A5.415.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%ASBPAspire Biopharma19.17%ENTOEntero Therapeutics12.30%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro1.39%ASBPAspire Biopharma5.80%ENTOEntero Therapeutics0.75%REVBRevelation Biosciences8.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.81 million3.75 millionNo DataASBPAspire BiopharmaN/A5.02 million4.73 millionN/AENTOEntero Therapeutics91.59 million3.34 millionN/AREVBRevelation Biosciences103.72 million3.42 millionNot OptionableASBP, ALZN, REVB, and ENTO HeadlinesRecent News About These CompaniesRevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardApril 6, 2026 | accessnewswire.comARevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyMarch 30, 2026 | oklahoman.comORevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 24, 2026 | accessnewswire.comARevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 19, 2026 | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025February 26, 2026 | accessnewswire.comARevelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comREVB stock drops 10% after company announces third reverse split in a yearJanuary 26, 2026 | msn.comRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026January 26, 2026 | accessnewswire.comARevelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross ProceedsJanuary 23, 2026 | accessnewswire.comARevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKIJanuary 21, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care NephrologyJanuary 14, 2026 | finanznachrichten.deRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)January 14, 2026 | accessnewswire.comARevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 12, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 8, 2026 | finanznachrichten.deRevelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 7, 2026 | accessnewswire.comARevelation Biosciences reaches quorum for Dec. 3 special meetingDecember 1, 2025 | msn.comRevelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special MeetingDecember 1, 2025 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This YearNovember 20, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, ALZN, REVB, and ENTO Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.09 +0.02 (+1.78%) As of 02:38 PM Eastern This is a fair market value price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Aspire Biopharma NASDAQ:ASBP$0.19 -0.01 (-3.50%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Entero Therapeutics NASDAQ:ENTO$2.52 +0.01 (+0.40%) As of 05/1/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Revelation Biosciences NASDAQ:REVB$1.02 -0.05 (-4.21%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
